Cargando…
Nanomodified Switch Induced Precise and Moderate Activation of CAR‐T Cells for Solid Tumors
Chimeric antigen receptor (CAR)‐T cell therapy is a transformative treatment against advanced malignancies. Unfortunately, once administrated in vivo, CAR‐T cells become out of artificial control, and fierce response to CAR‐T therapy may cause severe adverse events, represented by cytokine‐release s...
Autores principales: | Wang, Xinyue, Meng, Fanyan, Li, Xiang, Xue, Luxin, Chen, Anni, Qiu, Yuling, Zhang, Zhifan, Li, Lin, Liu, Fengcen, Li, Yishan, Sun, Zhichen, Chu, Yanhong, Xu, Ruihan, Yu, Lixia, Shao, Jie, Tian, Manman, Qian, Xiaoping, Liu, Qin, Liu, Baorui, Li, Rutian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10131841/ https://www.ncbi.nlm.nih.gov/pubmed/36755195 http://dx.doi.org/10.1002/advs.202205044 |
Ejemplares similares
-
Nanomodified Switch Induced Precise and Moderate Activation of CAR‐T Cells for Solid Tumors (Adv. Sci. 12/2023)
por: Wang, Xinyue, et al.
Publicado: (2023) -
In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors
por: Sun, Zhichen, et al.
Publicado: (2022) -
Tumor eradicated by combination of imiquimod and OX40 agonist for in situ vaccination
por: Chu, Yanhong, et al.
Publicado: (2021) -
In situ gelatinase-responsive and thermosensitive nanocomplex for local therapy of gastric cancer with peritoneal metastasis
por: Wang, Xinyue, et al.
Publicado: (2022) -
Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy
por: Zhu, Junmeng, et al.
Publicado: (2022)